{
 "counts": [
  {
   "trial": "T025",
   "measure": "MADRS (also at discharge)",
   "day": 3,
   "form": "count",
   "definition": "responders: MADRS reduction ≥ 50% from baseline (the primary outcome; a count of responders, not of participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T046",
   "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
   "day": 7,
   "form": "count",
   "definition": "remission: EPDS < 6 (from an antenatal EPDS > 9); events are remitters, not participants with depression",
   "counts": "improvement"
  },
  {
   "trial": "T046",
   "measure": "EPDS (PDS = EPDS > 9; remission EPDS < 6; total score)",
   "day": 42,
   "form": "count",
   "definition": "remission: EPDS < 6 (from an antenatal EPDS > 9); events are remitters, not participants with depression",
   "counts": "improvement"
  },
  {
   "trial": "T093",
   "measure": "MADRS (response = 50% reduction on POD 3; remission <=10)",
   "day": 1,
   "form": "difference",
   "definition": "odds ratio of MADRS response (≥ 50 % reduction from baseline), esketamine vs placebo; responders, not participants with depression (33 % vs 15 % responders)",
   "counts": "improvement"
  },
  {
   "trial": "T093",
   "measure": "MADRS (response = 50% reduction on POD 3; remission <=10)",
   "day": 3,
   "form": "count",
   "definition": "MADRS response, ≥ 50 % reduction from baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T112",
   "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
   "day": 3,
   "form": "count",
   "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T112",
   "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
   "day": 3,
   "form": "count",
   "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T112",
   "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
   "day": 5,
   "form": "count",
   "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T112",
   "measure": "MADRS (remission <=10 at POD 3 primary; response; scores at POD 3 and 5)",
   "day": 5,
   "form": "count",
   "definition": "response, MADRS reduction ≥ half of baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 1,
   "form": "count",
   "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 1,
   "form": "count",
   "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 2,
   "form": "count",
   "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 2,
   "form": "count",
   "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 3,
   "form": "count",
   "definition": "response, ≥ 50% decrease in MADRS from baseline (events are responders, not participants with depression)",
   "counts": "improvement"
  },
  {
   "trial": "T117",
   "measure": "MADRS",
   "day": 3,
   "form": "count",
   "definition": "remission, MADRS ≤ 10 (events are participants in remission, not with depression)",
   "counts": "improvement"
  }
 ],
 "contrasts": [
  {
   "trial": "T069",
   "form": "change_difference",
   "contrast": "ketamine_minus_control",
   "source_says": "Esketamine group minus Control group"
  },
  {
   "trial": "T081",
   "form": "difference",
   "contrast": "control_minus_ketamine",
   "source_says": "a significant decrease ... in the esketamine group compared with the control group (HADS-D: MD [SEM] 1.61 [0.61], 95 % CI 0.40-2.82)"
  },
  {
   "trial": "T084",
   "form": "difference",
   "contrast": "ketamine_minus_control",
   "source_says": "the S-ketamine group demonstrated ... a reduction in PHQ-9 scores (MD -1.0 [95% CI, -2.0 to 0])"
  },
  {
   "trial": "T093",
   "form": "difference",
   "contrast": "ketamine_versus_control",
   "source_says": "odds ratio of MADRS response, esketamine vs placebo"
  },
  {
   "trial": "T117",
   "form": "difference",
   "contrast": "ketamine_minus_control",
   "source_says": "Improvement in depressive symptoms ... significantly greater in the esketamine group (POD 1: aMD: -1.97, 95% CI: -3.505 to -0.433)"
  },
  {
   "trial": "T119",
   "form": "change_difference",
   "contrast": "control_minus_ketamine",
   "source_says": "P group (saline) minus ES group, change from baseline"
  }
 ],
 "note": "Annotations the author made by reading each entry's definition or source sentence: which counts count improvement (responders, remitters) rather than participants with depression, and which arm is subtracted from which in each between-arm difference. Differences without one are not used. Added in the second version, after the first version's reviews: which pain entries are not ratings of the patient's pain (analgesic use, an experimental pain threshold, or pain's interference with activity), so the positive control leaves them out as the plan leaves out opioid consumption; and the one trial whose own printed tests show that its printed dispersions are not standard deviations.",
 "pain": [
  {
   "trial": "T009",
   "measure": "Morphine consumption (mg)",
   "kind": "analgesic_use",
   "source_says": "morphine consumption (mg), Table 2"
  },
  {
   "trial": "T024",
   "measure": "analgesic effect at 24 and 48 h",
   "location": "Table 4, 'PCA times during 24H'",
   "kind": "analgesic_use",
   "source_says": "PCA times during 24 h"
  },
  {
   "trial": "T024",
   "measure": "analgesic effect at 24 and 48 h",
   "location": "Table 4, 'PCA times during 24-48H'",
   "kind": "analgesic_use",
   "source_says": "PCA times during 24-48 h"
  },
  {
   "trial": "T033",
   "measure": "effective PCIA presses within 48 h",
   "kind": "analgesic_use",
   "source_says": "effective presses of the patient-controlled analgesia pump"
  },
  {
   "trial": "T054",
   "measure": "PCIA presses in 24 h",
   "kind": "analgesic_use",
   "source_says": "PCA compressions"
  },
  {
   "trial": "T055",
   "measure": "effective PCIA presses at 48 h",
   "kind": "analgesic_use",
   "source_says": "total number of PCIA compressions in 48 hours"
  },
  {
   "trial": "T057",
   "measure": "rescue acetaminophen",
   "kind": "analgesic_use",
   "source_says": "rescue rate, n (%)"
  },
  {
   "trial": "T058",
   "measure": "effective PCIA presses",
   "kind": "analgesic_use",
   "source_says": "effective presses of the patient-controlled analgesia pump"
  },
  {
   "trial": "T074",
   "measure": "pressure pain threshold and tolerance (30 min, 24 h)",
   "kind": "pain_threshold",
   "source_says": "pressure pain threshold and tolerance (kgf)"
  },
  {
   "trial": "T103",
   "measure": "BPI pain severity and interference",
   "location": "Table 3 (BPI interference items, POD 1)",
   "kind": "pain_interference",
   "source_says": "BPI interference items"
  },
  {
   "trial": "T103",
   "measure": "BPI pain severity and interference",
   "location": "Table 3 (BPI interference items, POD 2)",
   "kind": "pain_interference",
   "source_says": "BPI interference items"
  },
  {
   "trial": "T109",
   "measure": "Sufentanil consumption (first 24h)",
   "kind": "analgesic_use",
   "source_says": "sufentanil consumption in the first 24 h"
  },
  {
   "trial": "T123",
   "measure": "Rescue analgesics (flurbiprofen axetil) within 48 h",
   "kind": "analgesic_use",
   "source_says": "rescue analgesics (flurbiprofen axetil)"
  }
 ],
 "dispersions": [
  {
   "trial": "T011",
   "source_says": "Data are presented as mean ± SD. Table 1: age 43.38 ± 0.95 against 41.40 ± 0.16 with t = 1.405; VAS on day 1 2.17 ± 0.24 against 3.75 ± 0.42 with t = −6.048 (60 per group). Table 2: PHQ-9 on day 1 2.68 + 0.73 against 3.37 + 0.91 with t = −2.051.",
   "reading": "The printed t statistics don't fit these dispersions as standard deviations (they would give t of about 15.9, −25.3, and −4.6) or as standard errors (about 2.1, −3.3, and −0.6), so the effects computed from them are not reliable."
  }
 ]
}